Kidney Biopsy Market Report 2026

The kidney biopsy market size has grown strongly in recent years. It will grow from $2.26 billion in 2025 to $2.38 billion in 2026 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to rising prevalence of chronic kidney disease, increasing incidence of glomerulonephritis and nephrotic syndrome, established clinical reliance on renal biopsy for diagnosis, growth in kidney transplant procedures, expansion of tertiary care hospitals.

The kidney biopsy market size is expected to see steady growth in the next few years. It will grow to $2.86 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to increasing burden of diabetes-related kidney disorders, growing adoption of ultrasound- and ct-guided biopsy techniques, rising demand for early kidney disease diagnosis, advancements in imaging technologies, expanding access to specialized nephrology care. Major trends in the forecast period include growing preference for minimally invasive kidney biopsy procedures, rising use of image-guided percutaneous biopsies, increasing demand for accurate renal disease diagnosis, expansion of biopsy procedures in transplant monitoring, improved safety and precision in renal tissue sampling.

The increasing incidence of renal cancer is anticipated to drive the growth of the kidney biopsy market in the coming years. Renal cancer involves the uncontrolled proliferation of abnormal cells within the kidneys. The growing prevalence of renal cancer is linked to factors such as lifestyle changes, exposure to environmental toxins, and improved diagnostic technologies that lead to higher detection rates. A kidney biopsy plays a key role in the diagnosis and management of renal cancer by confirming malignant cells, assessing tumor grade, guiding treatment decisions, monitoring therapeutic response, and offering prognostic insights. For example, according to Cancer Research UK, a UK-based cancer research organization, new cases of kidney cancer are projected to rise from around 16,300 in 2023 to nearly 21,900 by 2025. Thus, the rising burden of renal cancer is contributing to the expansion of the kidney biopsy market.

Leading companies in the kidney biopsy market are introducing advanced platforms integrated with artificial intelligence (AI) to improve diagnostic precision, optimize workflow efficiency, and enhance patient outcomes. Artificial intelligence (AI) strengthens kidney biopsy practices by advancing image analysis, supporting clinical diagnosis, assisting in treatment decision-making, enabling predictive insights, and accelerating research into kidney disorders. For example, in March 2024, Aiosyn, a Netherlands-based software company, introduced the NephroPath platform. The NephroPath platform leverages computational pathology algorithms to evaluate histological biomarkers in kidney biopsy samples, including tissue classification, quantification of interstitial fibrosis, and accurate identification and assessment of glomeruli. This AI-powered approach delivers standardized, comprehensive, and reproducible scoring of renal pathology biomarkers, addressing the limitations of conventional scoring techniques and reducing observer-related variability.

In March 2025, Aiosyn, a Netherlands-based pathology software company focused on artificial intelligence (AI)-driven diagnostic solutions, collaborated with Pramana to launch real-time AI processing for kidney biopsy evaluation. Through this collaboration, Aiosyn and Pramana plan to combine Aiosyn’s NephroPath AI algorithms with Pramana’s digital pathology platform to speed up kidney biopsy workflows, enhance diagnostic precision via automated tissue quantification, and improve operational efficiency by supporting on-device, edge-based processing. Pramana is a U.S.-based digital pathology technology company that specializes in automated whole-slide imaging systems integrated with edge-AI functionality.

Major companies operating in the kidney biopsy market are Cardinal Health, Medtronic plc, Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Becton Dickinson and Company, Boston Scientific Corporation, Olympus Corporation, Hitachi Ltd., Canon Medical Systems Corporation, Cook Medical, B. Braun Melsungen AG, Merit Medical Systems Inc., Argon Medical Devices Inc., Stryker Corporation, Integra LifeSciences Corporation, Leica Biosystems, Hologic Inc., Samsung Medison Co. Ltd., Mindray Medical International Limited, Terumo Corporation, Fujifilm Holdings Corporation.

North America was the largest region in the kidney biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kidney biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the kidney biopsy market by increasing the cost of imported biopsy needles, imaging guidance systems, and related procedural accessories. Percutaneous biopsy and image-guided biopsy segments are most affected, particularly in North America and Europe due to dependence on cross-border medical device supply chains. Hospitals and tertiary care centers face higher procurement and equipment maintenance costs, which may affect procedural pricing. However, tariffs have encouraged local manufacturing of biopsy devices, improved regional sourcing, and strengthened long-term supply chain resilience in renal diagnostics.

The kidney biopsy market research report is one of a series of new reports that provides kidney biopsy market statistics, including kidney biopsy industry global market size, regional shares, competitors with a kidney biopsy market share, detailed kidney biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the kidney biopsy industry. This kidney biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A kidney biopsy, also referred to as a renal biopsy, is a diagnostic medical procedure in which a small sample of kidney tissue is extracted and examined under a microscope. It is commonly used to diagnose kidney disorders, evaluate the extent of existing kidney diseases, or track how well a treatment is working. A kidney biopsy helps detect conditions such as glomerulonephritis, interstitial nephritis, and nephrotic syndrome, while offering important insights into the root causes of impaired kidney function.

The primary types of kidney biopsy include percutaneous biopsy and surgical biopsy. A percutaneous biopsy is performed by inserting a needle through the skin to obtain kidney tissue for analysis. This approach is widely used for multiple indications, including kidney failure, kidney transplantation, hematuria, and proteinuria, and is commonly carried out in hospitals, clinics, urology centers, tertiary care facilities, and other healthcare settings.

The kidney biopsy market consists of revenues earned by entities by providing services such as diagnostic biopsy, therapeutic biopsy, post-biopsy care and monitoring, and pathological analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The kidney biopsy market also includes sales of biopsy needles, biopsy guns, biopsy trays and kits, and biopsy specimen containers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.